Viral Clearance Market Updates

Viral Clearance Market size was valued at USD 535.6 Billion in 2023 and is poised to grow from USD 621.83 Billion in 2024 to USD 1764.37 Billion by 2032, growing at a CAGR of 16.1% during the forecast period (2025-2032).

The key players in the viral clearance market are working on continuous innovation in the field of research and development and product portfolio enhancement for better therapeutic outcomes for consumers. For example, In November 2021, Wuxi biologics announced the official opening of its advanced therapies testing facility, including 140,000 sq. ft laboratories to enhance the company’s Contract Testing, Developing, and manufacturing Organization businesses to meet the increasing needs of customers in cell and gene therapy industry. Companies are also focusing on mergers and acquisitions to expand their businesses. 'Charles River Laboratories ', 'Merck KGaA ', 'Texcell ', 'WuXi AppTec ', 'Sartorius AG ', 'Eurofins Scientific ', 'Vironova ', 'Syngene International ', 'Microbac Laboratories ', 'Creative Biolabs ', 'Nelson Labs ', 'SGS AG ', 'Lonza Group ', 'Bioscience Laboratories ', 'Labor Dr. Merk & Kollegen ', 'Gilead Sciences ', 'Poolbeg Pharma ', 'Incyte ', 'Genmab ', 'Biogen '

Growing Demand for Generics and Biosimilars: Increasing demand for biosimilars and generics is an ongoing trend. The need for sophisticated and cheap therapies for chronic diseases around the world is driving demand for recombinant non-glycosylation proteins in the biosimilars market; the application of cutting-edge technology to increase avenues.

In 2022, North America dominated the market by accounting for over 35% of the market share owing to the rapidly growing innovation in biotechnology and Life sciences. Growth of pharmaceuticals, increase in number of drug approvals, investments in research and development, and accuracy and flexibility of method in life sciences research has shaped the market growth in these areas. The growing prevalence of illnesses and an increased production of monoclonal antibodies, and government assistance for medication development are some of the primary reasons driving the viral clearance industry in the US with increasing pharmaceutical production supporting the growth of the region. Europe is expected to follow North America due to the strong foundation of research and development and pharmaceuticals and is expected to capture the second-largest share of the market.